← Back to Analyst Consensus 
TEVA Buy
TEVA PHARMACEUTICAL INDUSTRIES LTD
Current Price —
Implied Upside —
Analysts 7
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 2 reiterations from 3 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 15, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Oct 12, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Oct 1, 2026 | TD Cowen | initiate | — → Buy | — | 54% |
| Sep 23, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Sep 9, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Sep 4, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Aug 12, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 28, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| May 6, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Apr 30, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Apr 30, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Apr 30, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Apr 30, 2026 | Truist Securities | maintain | Buy → Buy | — | 55% |
| Apr 9, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Mar 4, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Feb 18, 2026 | Truist Securities | maintain | Buy → Buy | $42 | 55% |
| Feb 9, 2026 | Goldman Sachs | maintain | Buy → Buy | $45 | 54% |
| Jan 30, 2026 | Barclays | maintain | Overweight → Overweight | $38 | 53% |
| Jan 29, 2026 | Scotiabank | maintain | Sector Outperform → Sector Outperform | $40 | 55% |
| Jan 29, 2026 | Truist Securities | maintain | Buy → Buy | $38 | 55% |
| Jan 6, 2026 | Jefferies | maintain | Buy → Buy | $40 | 52% |
| Dec 22, 2025 | Piper Sandler | maintain | Overweight → Overweight | $40 | 54% |
| Dec 19, 2025 | Goldman Sachs | maintain | Buy → Buy | $35 | 54% |
| Dec 16, 2025 | JP Morgan | maintain | Overweight → Overweight | $35 | 55% |
| Dec 9, 2025 | B of A Securities | maintain | Buy → Buy | $32 | 53% |
| Dec 9, 2025 | Barclays | initiate | — → Overweight | $35 | 53% |
| Dec 8, 2025 | Goldman Sachs | maintain | Buy → Buy | $31 | 54% |
| Dec 5, 2025 | Scotiabank | initiate | — → Sector Outperform | $35 | 55% |
| Nov 6, 2025 | JP Morgan | maintain | Overweight → Overweight | $28 | 55% |
| Oct 3, 2025 | JP Morgan | maintain | Overweight → Overweight | $26 | 55% |
| Sep 24, 2025 | UBS | maintain | Buy → Buy | $26 | 54% |
| Jun 26, 2025 | UBS | maintain | Buy → Buy | $23 | 54% |
| Jun 6, 2025 | Goldman Sachs | initiate | — → Buy | $24 | 54% |
| May 28, 2025 | Truist Securities | initiate | — → Buy | $25 | 55% |
| May 12, 2025 | JP Morgan | upgrade | Neutral → Overweight | $23 | 55% |
| May 8, 2025 | B of A Securities | maintain | Buy → Buy | $22 | 53% |
| Mar 6, 2025 | B of A Securities | maintain | Buy → Buy | $20 | 53% |
| Jan 30, 2025 | UBS | maintain | Buy → Buy | $27 | 54% |
| Jan 30, 2025 | Barclays | maintain | Overweight → Overweight | $26 | 53% |
| Jan 23, 2025 | UBS | maintain | Buy → Buy | $30 | 54% |
| Jan 17, 2025 | Piper Sandler | maintain | Overweight → Overweight | $30 | 54% |
| Dec 18, 2024 | Barclays | maintain | Overweight → Overweight | $28 | 53% |
| Oct 23, 2024 | Barclays | maintain | Overweight → Overweight | $25 | 53% |
| Oct 21, 2024 | JP Morgan | maintain | Neutral → Neutral | $18 | 55% |
| Sep 3, 2024 | UBS | maintain | Buy → Buy | $26 | 54% |
| Aug 1, 2024 | Barclays | maintain | Overweight → Overweight | $22 | 53% |
| Jul 10, 2024 | UBS | maintain | Buy → Buy | $24 | 54% |
| Jun 27, 2024 | Jefferies | maintain | Buy → Buy | $23 | 52% |
| Jun 5, 2024 | Barclays | maintain | Overweight → Overweight | $21 | 53% |
| May 30, 2024 | B of A Securities | maintain | Buy → Buy | $21 | 53% |
Price Target Trend
Jul 24, 2026 Oct 26, 2026
EPS Estimates
+1q —
0q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days